Crossmark

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Crossref DOI link: https://doi.org/10.1186/s13148-019-0626-0

Published Online: 2019-02-20

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pineda, Begoña

Diaz-Lagares, Angel

Pérez-Fidalgo, José Alejandro

Burgués, Octavio

González-Barrallo, Inés

Crujeiras, Ana B.

Sandoval, Juan

Esteller, Manel

Lluch, Ana

Eroles, Pilar
Funding

Funding for this research was provided by:

Conselleria d'Educació, Investigació, Cultura i Esport (GV037/2016)

Instituto de Salud Carlos III (CB16/12/00481)

Ministerio de Economía, Industria y Competitividad, Gobierno de España (PI15/01617, PI18/01219, JR17/00016, CP17/00088)
License Information

Text and Data Mining valid from 2019-02-20
More Information

Article History

Received: 23 November 2018

Accepted: 31 January 2019

First Online: 20 February 2019

Ethics approval and consent to participate

: This study was approved by the local clinical Research Ethics Committee of the Hospital Clínico Universitario de Valencia /INCLIVA with the reference number 2014/178. Patients were requested to sign informed consent for tumor tissue molecular analysis and biobanking.

: Not applicable

: Authors BP, ADL, JA PF, ME, ALL, and PE are currently applying for a patent (application number EP18382390.5) relating the content of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.